Pfizer announces FDA approval of PREVNAR 20

Pfizer announced that the U.S. FDA has approved PREVNAR 20 for the prevention of invasive pneumococcal disease caused by the 20 Streptococcus pneumoniae serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR.